Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.

Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. Am J Hematol. 2024 07; 99(7):1257-1268.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols
Bortezomib
Dexamethasone
Female
Humans
Male
Middle Aged
Multiple Myeloma
Patient Reported Outcome Measures
Quality of Life

authors with profiles

Andrzej Jakubowiak